Progress in the treatment of Langerhans cell histiocytosis
- VernacularTitle:朗格汉斯细胞组织细胞增生症治疗进展
- Author:
Yongan NI
;
Lirong SUN
- Publication Type:Journal Article
- Keywords:
Langerhans cell histiocytosis;
single-system LCH;
multisystem LCH;
therapy
- From:
Journal of Clinical Pediatrics
2015;(3):291-294
- CountryChina
- Language:Chinese
-
Abstract:
Treatment of Langerhans cell histiocytosis (LCH) needs to be tailored for each individual patient according to LCH classiifcation currently. Single-system LCH (SS-LCH) has an excellent prognosis. However, there is a poor prognosis in multisystem LCH (MS-LCH) with risk organs (RO) involvement and refractory or recurrent LCH (Re-LCH). The prognosis of MS-LCH with RO involvement and Re-LCH has been improved markedly accompanying with progress of chemotherapy in recent years. The 5-year survival rate of MS-LCH reached above 80%, and the effective rate of Re-LCH reached above 60% after chemotherapy. Re-LCH can be cured by hematopoietic stem cell transplantation.
